- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07945522
Coffee and Arterial Stiffness Evaluation (CASE)
Coffee and Arterial Stiffness: Effects on Chronic Coffee Intake on Markers of Vascular Function, Cardiometabolic and Liver Health
This study aims to investigate whether twelve weeks of daily coffee consumption can improve blood vessel elasticity (arterial stiffness) in adults typical of the UK population who are currently non-habitual coffee consumers. Additionally, the effects on cardiometabolic disease risk markers, liver health markers, cognitive function and inter-individual genetic variations in response to coffee consumption will be examined.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Coffee has gained interest for its role in the prevention of non-communicable diseases such as heart and liver disease. Observational studies have reported that regular coffee consumption (2-4 cups per day) is associated with reduced risk of cardiovascular disease, type 2 diabetes, and overall mortality. However, these observational studies do not prove direct causality, requiring the need for well-designed randomized controlled trials. Additionally, most evidence comes from habitual coffee drinkers, and there is limited understanding of whether introducing coffee to non-habitual consumers can provide similar health benefits, particularly in individuals that are typically reflective of the UK population.
This trial aims to provide direct causal evidence to the potential health effects of coffee consumption on risk markers for the development of cardiometabolic disease (such as type 2 diabetes, heart and liver diseases). To ensure the potential impact of habitual coffee consumption is minimised as a confounding factor, non-habitual coffee consumers (coffee-naïve) will be recruited. To maximise recruitment and adherence in the study, the coffee intervention is being provided in a tablet formulation (as opposed to a liquid drink formulation typical taken). In a previous pilot study conducted in 2025, the biological activity of the coffee tablet formulation is expected to be deemed bioequivalent compared to the liquid drink.
A 2-armed, double-blind, randomized controlled parallel trial will be conducted in participants that reflect the general population (estimated using UK representative data from the National Diet and Nutrition Survey). The primary outcome is the effect of coffee consumption on arterial stiffness (measured by cardio-ankle vascular index (CAVI)), an important prognostic marker of vascular aging and cardiovascular disease. Secondary outcomes will assess the impact of coffee consumption on cardiometabolic disease risk markers, liver health markers, cognitive function and genetic factors driving inter-individual response. This will be compared to a coffee-free control.
Study participation will require two visits to the Hugh Sinclair Unit of Human Nutrition (HSU), University of Reading, UK. For the first visit, participants will arrive having fasted overnight, consumed a standardised evening meal, and having followed lifestyle restrictions in the preceding days. Baseline anthropometric measures, blood pressure, CAVI measures, cognitive functions scores will be performed in addition to collecting a fasting blood sample (up to 50ml in total). Additionally, participants will be asked to provide a 24-hour urine sample during the same visit. At the end of the first study visit, participants will be randomised, stratified by age, gender and body-mass index (BMI), and receive their intervention bottles containing tablets to take on a daily basis over the 12-week study period. The second study visit will repeat the same procedures outlined at the end of 12 weeks.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Charlotte E Mills, PhD
- Número de telefone: 7108 0118378
- E-mail: c.e.mills@reading.ac.uk
Estude backup de contato
- Nome: Kim G Jackson, PhD
- Número de telefone: 5361 0118378
- E-mail: k.g.jackson@reading.ac.uk
Locais de estudo
-
-
Berkshire
-
Reading, Berkshire, Reino Unido, RG6 6DZ
- Hugh Sinclair Unit of Human Nutrition
-
Contato:
- Sandra Ilett
- Número de telefone: 7771 0118378
- E-mail: nutritionvolunteers@reading.ac.uk
-
Subinvestigador:
- Kim G Jackson, PhD
-
Subinvestigador:
- Anisha Wijeyesekera, PhD
-
Subinvestigador:
- TiJesu Akeredolu, MPharm
-
Subinvestigador:
- Lolwa Alawadhi, MSc
-
Subinvestigador:
- Altaf Farraj, MSc
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Males and females
- Aged between 40 to 75 years
- Low habitual coffee consumption (less than 3 cups per week) (over the past 4-week period)
- Body mass index (BMI) between 18.5-32.0kg/m^2 (inclusive)
- Total cholesterol ≤6.5 mmol/L
- Fasting triglycerides <1.7 mmol/L
- Fasting glucose ≤ 6.1 mmol/L
- Blood pressure 90/60 - 140/90 mmHg (inclusive)
Exclusion Criteria:
- Sensitivity to coffee or caffeine
- Regular consumption of caffeinated products or drinks; including tea, energy drinks or caffeine tablets (over 350 mg caffeine per week) or unwilling to stop drinking coffee during the intervention period
- Current smoking and vaping use
- Medical history of chronic diseases (cancer, hypertension, type 2 diabetes, ischaemic attacks and/or any other cardiovascular related diseases, gastro-intestinal disorders, hyperlipidaemia, kidney or liver disease)
- Haemoglobin <115 g/L for females or <130 g/L for males
- Prescribed any medication relating to the study outcome measures (such as blood pressure lowering, anti-inflammatories or blood thinners)
- Current use or past use of antibiotics within 6 months
- Drinking more than the recommended intake for alcohol (>14 units of alcohol per week)
- Current undertaking or planning to start a weight reducing regimen
- Taking any supplements (vitamins, minerals, prebiotics and probiotics)
- Any other medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention and metabolic study (e.g. pacemaker)
- Parallel participation in another intervention study
- Pregnancy, planning a pregnancy in the next 6 months or breastfeeding
- NHS blood donation (470 ml) in the last 3 months
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Coffee
This group will consume 5.4g of a commercially available instant coffee, provided in a tablet formulation (9 tablets daily). |
Commercially available instant coffee (5.4g), will be provided as 9 tablets (equivalent to 3 tablets per cup, therefore total 3 cups daily). This is to be consumed by the participant on a daily basis for 12 weeks. The intervention can be taken spaced throughout the day as per participant convenience, with a preference of consuming all 9 tablets by 2pm each day. |
|
Comparador de Placebo: Control
This group will consume a coffee-free control, provided in a tablet formulation (9 tablets daily). |
Coffee-free control (microcrystallinecellulose (non-active)) will be provided as 9 tablets. This is to be consumed by the participant on a daily basis for 12 weeks. The intervention can be taken spaced throughout the day as per participant convenience, with a preference of consuming all 9 tablets by 2pm each day. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Cardio-ankle vascular index
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Cardio-ankle vascular index (CAVI) score will be measured by the attachment of an inflatable blood pressure cuff to each limb (right brachial, left brachial, right ankle, left ankle) and attachment of a PCG microphone (measuring heart sounds during the cardiac cycle) on the sternum using a VaSera VS-2000 device on study visits. No fixed scale range is present, lower scores indicate an improvement in outcome. |
Week 0 (baseline), Week 12 (final visit)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Fasting coffee bioactives concentrations and polyphenol metabolite concentrations
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Plasma concentrations of key coffee bioactives (e.g. caffeine, chlorogenic acids, trigonelline) and polyphenol metabolites will be measured from a fasting blood sample collected on study visits. These samples will be analysed via liquid chromatography mass spectrometry, concentration unit of measure (microgram per millilitre). |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting lipid profile concentrations
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Serum total cholesterol (TC), triacylglycerol, high-density lipoprotein cholesterol (HDL-C), non-esterified fatty acids and apolipoprotein B will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (micromolar per litre). Low-density cholesterol concentrations will be calculated from TC concentrations and HDL-C concentrations using the Friedewald formula. |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting insulin concentrations
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Serum insulin will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay, concentration unit of measure (IU per millilitre). |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting glucose concentrations
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Serum glucose will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (millimolar per millilitre). |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting Haemoglobin A1C concentrations of glycaemic control measures
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Haemoglobin (Hb) A1C will be measured from a fasting whole blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (%). |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting estimate of insulin resistance
Prazo: Week 0 (baseline), Week 12 (final visit)
|
HOMA-IR (Homeostasis model assessment estimated insulin resistance) will be calculated using the fasting glucose and insulin data. Scale range: <1 - 5+, lower scores indicate an improvement in outcome. |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting estimate of insulin sensitivity
Prazo: Week 0 (baseline), Week 12 (final visit)
|
QUICKI (Quantitative Insulin Sensitivity Check Index) will be calculated using the fasting glucose and insulin data. Scale range: <0.25 - 0.45+, higher scores indicate an improvement in outcome. |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting liver enzyme and function concentrations
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Serum alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate transferase (AST), gamma-glutamyl transferase (GGT) and total bilirubin will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (unit per liter). |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting concentrations of kidney function measures
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Serum uric acid and creatinine will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (micromolar per litre). |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting concentrations of inflammatory markers
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Serum interleukin (IL) 1b, IL-6, high sensitivity C-reactive protein, tumour necrosis factor alpha, intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion protein 1 (VCAM-1) will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay, concentration unit of measure (picogram per millilitre) |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting brain-derived neurotrophic factor concentrations
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Serum brain-derived neurotrophic factor will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay. |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting vascular endothelial growth factor concentrations
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Serum vascular endothelial growth factor will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay. |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting oxidised low density lipoprotein cholesterol concentrations
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Plasma concentrations of oxidised low density cholesterol will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay. |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting trimethylamine N-oxide concentrations
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Plasma concentrations of trimethylamine N-oxide will be measured from a fasting blood sample collected on study visits. These samples will be analysed via liquid chromatography mass spectrometry. |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting gut hormone concentrations
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Plasma concentrations of C-peptide, gastric inhibitory polypeptide, glucagon-like receptor-1 and ghrelin will be measured from a fasting blood sample collected on study visits. These samples will be analysed via Luminex |
Week 0 (baseline), Week 12 (final visit)
|
|
Fasting estimated nitric oxide concentrations
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Plasma estimated concentrations of nitric oxide (nitrate and nitrite) will be measured from a fasting blood sample collected on study visits. These samples will be analysed via chemiluminescence/LCMS. |
Week 0 (baseline), Week 12 (final visit)
|
|
Urinary metabolomics
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Untargeted metabolomics will be performed on pooled 24 hour urine samples collected on day prior to study visits. These samples will be analysed via liquid chromatography mass spectrometry and nuclear magnetic resonance spectroscopy |
Week 0 (baseline), Week 12 (final visit)
|
|
Urinary creatinine concentrations
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Urinary concentrations of creatinine will be measured from pooled 24 hour urine samples collected on day prior to study visits. These samples will be analysed via clinical chemistry analyser |
Week 0 (baseline), Week 12 (final visit)
|
|
Urinary F2-isoprostanes concentrations
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Urinary concentrations of F2-isoprostanes will be measured from pooled 24 hour urine samples collected on day prior to study visits. These samples will be analysed via liquid chromatography mass spectrometry. |
Week 0 (baseline), Week 12 (final visit)
|
|
Identification of gut microbiota composition
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Gut microbiome composition will be identified and assessed using RNA sequencing from a stool sample, provided on day prior to study visits. |
Week 0 (baseline), Week 12 (final visit)
|
|
Cognitive function
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Assessment of cognitive function will be performed using Millisecond Inquisit 7 software on study visits. No fixed scale range is present, higher scores indicate an improvement in outcome. |
Week 0 (baseline), Week 12 (final visit)
|
|
Clinic blood pressure
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Blood pressure will be measured using a blood pressure monitor on study visits. |
Week 0 (baseline), Week 12 (final visit)
|
|
Ankle Brachial Index
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Ankle Brachial Index will be measured by the attachment of an inflatable blood pressure cuff to each limb (right brachial, left brachial, right ankle, left ankle) using a VaSera VS-2000 device on study visits. Scale range: <0.5 - 1.4+, higher scores indicate an improvement in outcome. |
Week 0 (baseline), Week 12 (final visit)
|
|
Lean body mass
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Body lean mass will be measured by bioelectrical impedance using the Tanita scale on study visits. |
Week 0 (baseline), Week 12 (final visit)
|
|
Body fat percentage
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Body fat percentage will be measured by bioelectrical impedance using the Tanita scale on study visits. |
Week 0 (baseline), Week 12 (final visit)
|
|
Body-mass index
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Height will be measured using a stadiometer on the first study visit. Weight will be measured using the Tanita scale on both study visits. |
Week 0 (baseline), Week 12 (final visit)
|
|
Hip and waist circumference
Prazo: Week 0 (baseline), Week 12 (final visit)
|
Hip and waist circumference will be measured using a non-stretch tape on study visits. |
Week 0 (baseline), Week 12 (final visit)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Abbe Davy, BSc, University of Reading
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- UREC 26/31
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
All anonymised IPD that underlie results in a publication and analytical code for statistical analysis
Prazo de Compartilhamento de IPD
Anonymised data will be made available on reasonable request to the study Chief Investigator one year after manuscripts have been published.
Critérios de acesso de compartilhamento IPD
For data sharing and preservation, anonymised IPD will be archived in the University of Reading Research Data Archive. Access will be overseen by the project Chief Investigator (Associate Professor Charlotte Mills).
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- ANALYTIC_CODE
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .